Contents    Cover    Publication Date: 12 Nov 2020
Year 2020 - Volume 30 - Issue 3

Open Access

Peer Reviewed

ORIGINAL RESEARCH
152 Viewed100 Downloaded

Markers That are Used for Allergic Diseases Can the Be Used in Preeclampsia?

Full Text PDF  
J Clin Obstet Gynecol. 2020;30(3):100-5
DOI: 10.5336/jcog.2020-74393
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: We aimed to investigate the relationship between inflammatory markers used for allergic diseases and preeclampsia. Material and Methods: This retrospective case-control study included 162 patients comprising 81 patients in the control group and 81 patients in the preeclampsia group. The preeclampsia group was constituted by 40 patients with mild preeclampsia and 41 with severe preeclampsia. The basophil, eosinophil, eosinophil-basophil ratio (EBR), eosinophil-lymphocyte ratio (ELR), and basophil-lymphocyte ratio (BLR) values used in this study were taken into account before the initiation of any medical or surgical procedure. Results: EBR was significantly lower in the preeclampsia group than in the control group (p=0.033). Basophil (p=0.049) and BLR (p=0.029) values were significantly higher in the preeclampsia group than in the control group. When the control group and preeclampsia subgroups were compared, ELR and EBR had significantly different between three groups ((p=0.039 and p=0.010 respectively) but in binary comparison no difference was found. As preeclampsia severity increased, EBR decreased, and ELR increased gradually. To predict preeclampsia, the receiver operating characteristic curve (ROC) analysis was used. The ROC analysis results of EBR was found as sensitivity 51.90%, and specificity 69.1% (AUC: 0.597, 95% CI: 0.51-0.68), and BLR was found as sensitivity 62.85%, and specificity 59.78% (AUC: 0.600, 95% CI: 0.51-0.69). Conclusion: Allergy-related mechanisms may also play a role in the pathogenesis of preeclampsia. Allergic markers may be considered in the diagnosis and research of preeclampsia.
REFERENCES:
  1. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA. 2002;26;287(24):3183-6. [Crossref]  [PubMed] 
  2. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013;7;347:f6564. [Crossref]  [PubMed]  [PMC] 
  3. Gleicher N. Why much of the pathophysiology of preeclampsia-eclampsia must be of an autoimmune nature. Am J Obstet Gynecol. 2007;196(1):5.e1-7. [Crossref]  [PubMed] 
  4. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 200;22;344(12):867-72. [Crossref]  [PubMed] 
  5. Madazlı R, Bulut B, Aydın B, Demirayak G, Kucur M. [First-trimester maternal serum metastin levels, chitotriosidase activity and uterine artery Doppler findings in preeclampsia]. Turkiye Klinikleri J Gynecol Obst. 2012;22(4):211-5.
  6. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med. 2001;7(9):1003-9. [Crossref]  [PubMed] 
  7. Einarsson JI, Sangi-Haghpeykar H, Gardner MO. Sperm exposure and development of preeclampsia. Am J Obstet Gynecol. 2003;188(5):1241-3. [Crossref]  [PubMed] 
  8. Klonoff-Cohen HS, Savitz DA, Cefalo RC, McCann MF. An epidemiologic study of contraception and preeclampsia. JAMA. 1989;8;262(22):3143-7. [Crossref]  [PubMed] 
  9. Masoudian P, Nasr A, de Nanassy J, Fung-Kee-Fung K, Bainbridge SA, El Demellawy D, et al. Oocyte donation pregnancies and the risk of preeclampsia or gestational hypertension: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016;214(3):328-39. [Crossref]  [PubMed] 
  10. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126(1):39-44. [Crossref]  [PubMed]  [PMC] 
  11. Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am. 2007;27(3):357-75. [Crossref]  [PubMed]  [PMC] 
  12. Kara A, Guven M, Yilmaz MS, Demir D, Elden H. Are neutrophil, platelet and eosinophil-to-lymphocyte ratio and red blood cell distribution width can be used for nasal polyposis? Eur Arch Otorhinolaryngol. 2018;275(2):409-13. [Crossref]  [PubMed] 
  13. Yenigün A. Assessment of patients with nasal polyposis by the neutrophil-to-lymphocyte ratio and eosinophil-to-lymphocyte ratio. Kulak Burun Bogaz Ihtis Derg. 2015;25(4):193-9. [Crossref]  [PubMed] 
  14. Zhang XY, Simpson JL, Powell H, Yang IA, Upham JW, Reynolds PN, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy. 2014;44(9):1137-45. [Crossref]  [PubMed] 
  15. Brescia G, Barion U, Zanotti C, Cinetto F, Giacomelli L, Martini A, et al. Blood eosinophil-to-basophil ratio in patients with sinonasal polyps: does it have a clinical role? Ann Allergy Asthma Immunol. 2017;119(3):223-6. [Crossref]  [PubMed] 
  16. Mtali YS, Lyimo MA, Luzzatto L, Massawe SN. Hypertensive disorders of pregnancy are associated with an inflammatory state: evidence from hematological findings and cytokine levels. BMC Pregnancy Childbirth. 2019;9;19(1):237. [Crossref]  [PubMed]  [PMC] 
  17. Xu Z, Zhao F, Lin F, Xiang H, Wang N, Ye D, et al. Preeclampsia is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator. Fertil Steril. 2014;102(1):282-90.e4. [Crossref]  [PubMed] 
  18. Ilmarinen P, Kankaanranta H. Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin Pharmacol Toxicol. 2014;114(1):109-17. [Crossref]  [PubMed] 
  19. ACOG practice bulletin no. 202: gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133(1):e1-e25. [PubMed] 
  20. Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91. [Crossref]  [PubMed] 
  21. Eifan AO, Durham SR. Pathogenesis of rhinitis. Clin Exp Allergy. 2016;46(9):1139-51. [Crossref]  [PubMed] 
  22. Christodoulopoulos P, Cameron L, Durham S, Hamid Q. Molecular pathology of allergic disease. II: upper airway disease. J Allergy Clin Immunol. 2000;105(2 Pt 1):211-23. [Crossref]  [PubMed] 
  23. Naclerio RM, Proud D, Togias AG, Adkinson Jr NF, Meyers DA, Kagey-Sobotka A, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985;11;313(2):65-70. [Crossref]  [PubMed] 
  24. Yamanishi Y, Karasuyama H. Basophil?derived IL?4 plays versatile roles in immunity. Semin Immunopathol. 2016;38(5):615-22. [Crossref]  [PubMed] 
  25. Otsuka A, Nonomura Y, Kabashima K. Roles of basophils and mast cells in cutaneous inflammation. Semin Immunopathol. 2016;38(5):563-70. [Crossref]  [PubMed] 
  26. Yalcin AD, Kargi A, Gumuslu S. Blood eosinophil and platelet levels, proteomics patterns of trail and CXCL8 correlated with survival in bevacizumab treated metastatic colon cancers. Clin Lab. 2014;60(2):339-40. [Crossref]  [PubMed] 
  27. Wei Y, Zhang X, Wang G, Zhou Y, Luo M, Wang S, et al. The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage I-III colorectal cancer. Asia Pac J Clin Oncol. 2018;14(5):e243-e51. [Crossref]  [PubMed] 
  28. Lurie S, Frenkel E, Tuvbin Y. Comparison of the differential distribution of leukocytes in preeclampsia versus uncomplicated pregnancy. Gynecol Obstet Invest. 1998;45(4):229-31. [Crossref]  [PubMed] 
  29. Canzoneri BJ, Lewis DF, Groome L, Wang Y. Increased neutrophil numbers account for leukocytosis in women with preeclampsia. Am J Perinatol. 2009;26(10):729-32. [Crossref]  [PubMed]  [PMC] 
  30. Yavuzcan A, Caðlar M, Ustün Y, Dilbaz S, Ozdemir I, Yildiz E, et al. Mean platelet volume, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in severe preeclampsia. Ginekol Pol. 2014;85(3):197-203. [Crossref]  [PubMed] 
  31. Gambichler T, Brown V, Steuke AK, Schmitz L, Stockfleth E, Susok L, et al. Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. J Eur Acad Dermatol Venereol. 2018;32(6):972-7. [Crossref]  [PubMed] 
  32. Örgül G, Aydýn Haklý D, Özten G, Fadiloðlu E, Tanacan A, Beksaç MS, et al. First trimester complete blood cell indices in early and late onset preeclampsia. Turk J Obstet Gynecol. 2019;16(2):112-7. [Crossref]  [PubMed]  [PMC]